Literature DB >> 8947927

Cyclazocine revisited.

S Archer1, S D Glick, J M Bidlack.   

Abstract

Recently synthesized compounds which have long-term mu antagonist activity and short-term kappa agonist effects prevent self-administration of cocaine and morphine in rats. Cyclazocine, a compound synthesized in 1962 and studied in animals and man in the 1960's and in the early 1970's is a mu antagonist in rats and man and is a potent kappa agonist in both species. It also prevents self-administration of cocaine and morphine in rats. Although it produces unpleasant side effects in man, subjects become tolerant to these side effects but not to the antagonistic actions of the drug after prolonged administration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8947927     DOI: 10.1007/bf02532378

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  15 in total

1.  Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids.

Authors:  R D Spealman; J Bergman
Journal:  J Pharmacol Exp Ther       Date:  1992-05       Impact factor: 4.030

2.  Role of opioid antagonists in treating intravenous cocaine abuse.

Authors:  T R Kosten; H D Kleber; C Morgan
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

3.  Kappa opioid inhibition of morphine and cocaine self-administration in rats.

Authors:  S D Glick; I M Maisonneuve; J Raucci; S Archer
Journal:  Brain Res       Date:  1995-05-29       Impact factor: 3.252

4.  An experimental study in the treatment of narcotic addicts with cyclazocine.

Authors:  W R Martin; C W Gorodetzky; T K McClane
Journal:  Clin Pharmacol Ther       Date:  1966 Jul-Aug       Impact factor: 6.875

5.  Very long-acting narcotic antagonists: the 14 beta-p-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives.

Authors:  M D Aceto; E R Bowman; E L May; L S Harris; J H Woods; C B Smith; F Medzihradsky; A E Jacobson
Journal:  Arzneimittelforschung       Date:  1989-05

6.  Antinociceptive properties of two alkylating derivatives of morphinone: 14 beta-(thioglycolamido)-7,8-dihydromorphinone (TAMO) and 14 beta-(bromoacetamido)-7,8-dihydromorphinone (H2BAMO).

Authors:  Q Jiang; A Seyed-Mozaffari; S Archer; J M Bidlack
Journal:  J Pharmacol Exp Ther       Date:  1992-08       Impact factor: 4.030

7.  Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies.

Authors:  D P Devine; P Leone; D Pocock; R A Wise
Journal:  J Pharmacol Exp Ther       Date:  1993-09       Impact factor: 4.030

8.  Buprenorphine suppresses cocaine self-administration by rhesus monkeys.

Authors:  N K Mello; J H Mendelson; M P Bree; S E Lukas
Journal:  Science       Date:  1989-08-25       Impact factor: 47.728

9.  Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.

Authors:  G Di Chiara; A Imperato
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

10.  14 alpha,14' beta-[Dithiobis[(2-oxo-2,1-ethanediyl)imino]]bis (7,8-dihydromorphinone) and 14 alpha,14' beta-[dithiobis[(2-oxo-2,1- ethanediyl)imino]]bis[7,8-dihydro-N-(cyclopropylmethyl)normorphinone]: chemistry and opioid binding properties.

Authors:  S Archer; A Seyed-Mozaffari; Q Jiang; J M Bidlack
Journal:  J Med Chem       Date:  1994-05-27       Impact factor: 7.446

View more
  20 in total

Review 1.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 2.  Kappa opioids as potential treatments for stimulant dependence.

Authors:  Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

3.  Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.

Authors:  Xuemei Peng; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2007-04-04       Impact factor: 7.446

Review 4.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

5.  The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats.

Authors:  Aashish S Morani; Amy Ewald; Katherine M Prevatt-Smith; Thomas E Prisinzano; Bronwyn M Kivell
Journal:  Eur J Pharmacol       Date:  2013-11-04       Impact factor: 4.432

6.  Aminothiazolomorphinans with mixed κ and μ opioid activity.

Authors:  Tangzhi Zhang; Zhaohua Yan; Anna Sromek; Brian I Knapp; Thomas Scrimale; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2011-02-25       Impact factor: 7.446

7.  Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 9: Synthesis, characterization and molecular modeling of pyridinyl isosteres of N-BPE-8-CAC (1), a high affinity ligand for opioid receptors.

Authors:  Melissa A VanAlstine; Mark P Wentland; Juan Alvarez; Qing Cao; Dana J Cohen; Brian I Knapp; Jean M Bidlack
Journal:  Bioorg Med Chem Lett       Date:  2013-02-08       Impact factor: 2.823

Review 8.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

9.  Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar Ki range: oxygenated N-(2-[1,1'-biphenyl]-4-ylethyl) analogues of 8-CAC.

Authors:  Mark P Wentland; Sunjin Jo; Joseph M Gargano; Melissa A VanAlstine; Dana J Cohen; Jean M Bidlack
Journal:  Bioorg Med Chem Lett       Date:  2012-10-27       Impact factor: 2.823

Review 10.  Bi- or multifunctional opioid peptide drugs.

Authors:  Peter W Schiller
Journal:  Life Sci       Date:  2009-03-11       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.